Jay Chhablani, MD

Jay Chhablani, MD, on multimodal imaging, OCT biomarkers, and the importance of early diagnosis as treatment options emerge

Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.